Skip to content
AnalystLens

PROCTER & GAMBLE Co 8-K Report (May 9, 2003)

Reports
Other Events
Filing Date
Filed May 9, 2003
Period End
May 9, 2003
Security
PG
In the record · 2016–202610-K1210-Q328-K226

PG filed 12 annual reports (10-K), 32 quarterly reports (10-Q) and 226 current reports (8-K) between 2016 and 2026.

  1. FY2019 annual report10-K · Aug ’19Aug ’19
  2. Leadership change8-K · Jan ’22Jan ’22
  3. Leadership change8-K · Dec ’25Dec ’25

Summary

Summary of the 8-K filed May 9, 2003. Cited figures are marked; the original filing is the authoritative source.

Procter & Gamble's May 9, 2003 Form 8-K, filed under Regulation FD, reports that the management board of Wella AG has accepted P&G's tender offer for Wella's ordinary and voting shares.

Wella's formal response statement, published under Section 27 of German takeover law, says the offer is legally sound and fair to both ordinary and preference shareholders. It also notes that the Wella management board members intend to tender their own holdings. A third-party fairness opinion from Greenhill Investment Bank, commissioned by Wella, supports the offer's fairness.

P&G's vice-chairman Bruce Byrnes characterized the acceptance as additional confirmation that the offer is adequate and fair. The transaction is structured in stages. P&G signed an agreement on March 18, 2003 to buy 77.6%a of Wella AG's voting stock from its majority shareholders.

On April 28, 2003, P&G launched a tender offer at EUR 92.25 per voting share and EUR 65 per preference share. The initial tender period runs through May 28, 2003, followed by an extended two-week acceptance period under German law that is expected to begin June 6, 2003. The deal remains subject to regulatory review and government approvals in various markets, including the European Union and the United States.

For investors, the filing is primarily a positive procedural milestone that reduces execution risk around the Wella acquisition, which expands P&G's beauty care portfolio. The filing does not disclose the total transaction value, financing details, or expected synergies, and it contains no new financial results. Closing still depends on regulatory clearances and tender participation, so the outcome remains uncertain until those conditions are satisfied.

Key Highlights

  1. Wella's management board has accepted P&G's tender offer and publicly stated the offer is legally sound and fair to both ordinary and preference shareholders.
  2. Wella's management board members intend to tender their own ordinary and preference shares into the offer.
  3. A fairness opinion from Greenhill Investment Bank, commissioned by Wella, concluded the offer is fair.
  4. P&G has already signed an agreement to acquire 77.6% of Wella AG's voting stock from its majority shareholders (signed March 18, 2003).
  5. Tender offer prices are EUR 92.25 per voting share and EUR 65 per preference share, launched April 28, 2003.
  6. The tender period runs until May 28, 2003, with an extended two-week acceptance period expected to start June 6, 2003 under German law.
  7. Completion remains subject to regulatory review and government approvals in various markets, including the European Union and the United States.

Frequently Asked Questions

  1. What did P&G announce in this 8-K filing?

    P&G announced that the management board of Wella AG accepted its tender offer for Wella's ordinary and voting shares. The filing was made under Regulation FD to disclose the news release to all investors simultaneously.

  2. What are the offer prices for Wella shares?

    P&G's tender offer, launched April 28, 2003, is EUR 92.25 per Wella voting share and EUR 65 per Wella preference share.

  3. When does the tender offer end?

    The initial tender period runs until May 28, 2003. An extended two-week acceptance period, required by German law, is expected to begin on June 6, 2003.

  4. What conditions remain before the acquisition closes?

    The deal is subject to normal regulatory review and government approvals in various markets, including the European Union and the United States. The filing does not specify the timing of these approvals.

  5. Does the filing indicate the financial impact on P&G?

    No. The filing does not disclose the total transaction value, financing arrangements, expected synergies, or pro forma financial effects. Investors would need to look to other disclosures for those details.